Biotech | April 08, 2026
Stipple Bio raises $100M Series A to advance next-gen cancer therapies
The new capital is expected to fund the company through 2029
The new capital is expected to fund the company through 2029
Interchangeable biosimilars to Prolia and Xgeva target osteoporosis and cancer-related bone complications in a $5 billion U.S. market
Chronic GVHD is a serious and potentially life-threatening condition, imposing profound physical and emotional burdens on a substantial proportion of patients following allogeneic stem cell transplantation
The collaboration promises expanded funding for Thai universities, research institutes, companies, and global research partners working in Thailand
Under the collaboration, Symeres will test Ambagon’s newly designed molecular glues using in vitro assays and mechanistic studies
As demand for GLP-1 therapies explodes, India’s drug regulator moves to curb advertising amid rising concerns over misuse, access, and long-term impact
Health of the Nation 2026, based on over 3 million assessments, finds rising diabetes, obesity, and hidden cardiac risks in under-30s and working professionals
Searches for diabetes, heart conditions, and metabolism-related risks are rising sharply, with Tier 2 cities outpacing metros in specialist consultations
MoU to deploy Qure.ai’s chest X-ray solution across 20 government facilities aims to improve early detection in urban and rural populations
New facility in Sector 51 offers advanced, affordable, and patient-centric dialysis services for NCR patients
Subscribe To Our Newsletter & Stay Updated
